Certolizumab pegol has been approved in Canada for treating adults with plaque psoriasis. The U.K. has also issued its final guidance for the treatment’s use…
Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World
NEW YORK (Reuters Health)—Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study. “Previous studies have shown that denosumab is more efficacious than alendronate in increasing bone mineral density (BMD), possibly the best proxy outcome for subsequent fracture risk. However, previous studies were underpowered…
IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results
NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical relapse, researchers from Spain report. Recent studies have demonstrated the effectiveness and safety of infliximab biosimilars in patients with IBD, but there are limited data about the effectiveness…
Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis
Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…
Mirikizumab Promising for Plaque Psoriasis
During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…
Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
Health Canada has approved adalimumab for treating chronic non-infectious anterior uveitis in patients 2 years and older…
FDA Approves Guselkumab Injector
The FDA has approved a single-press, self-injection device for a 100-mg dose of guselkumab for adults with moderate to severe plaque psoriasis…
Biosimilars: How Do They Affect Patient Care & Safety?
CHICAGO—“We have got to get over this hump. We have got to try new stuff,” said Jacqueline M. Fritz, RN, MSN, CNS, to the audience gathered on the final day of the 2018 ACR/ARHP Annual Meeting, referring to the subject of biosimilars. Ms. Fritz, the owner and coordinator of education at the Medical Advancement Center…
Why & How Our Biologic Drug Discussion with Patients Should Evolve
As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…
Biosimilar ABP 798 Promising for RA
A clinical trial in RA patients has established the pharmacokinetic similarity of ABP 798 and rituximab…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 40
- Next Page »